We studied the crucial role of transforming growth factor beta-activated kinase 1 (TAK-1) in regulating RPE cells that form fibrotic tissue, and how modulating this process could help prevent fibrosis. We aim to target RPE cell differentiation using the TAK1 inhibitor OM-101, a novel small molecule that interferes with the pathological mechanism involved, thus halting this process and subsequently decreasing the chances of PVR. OM-101 has already demonstrated significant safety and efficacy in in vitro and in vivo studies. We demonstrated that two intravitreal injections of OM-101 significantly reduced the fibrotic response underlying PVR pathophysiology. Safety experiments demonstrated that OM-101 is safe for ocular administration with no systemic side effect. OM-101 was also proven to decrease fibrotic response in other conditions such as inflammation of hepatocyte cells and intestinal fibrosis.